Kwangdong's B hepatitis vaccine to be cancelled.

Published: 2005-08-18 06:57:00

Updated: 2005-08-18 06:57:00

The product registration of Biken HB injection, a gene recombinant type of B hepatitis vaccine of Kwangdong pharm. co. has been cancelled in a KFDA's administrative measure because of no compliance to the product review.

The KFDA said that Kwangdong had never imported Biken HB injection nor su...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK